Progress on chemotherapy for triple negative breast cancer

倪晨; 李婷; 吴振华; 胡夕春

doi:10.3969/j.issn.1007-3969.2014.04.013

您当前的位置：

首页 >

文章列表页 >

Progress on chemotherapy for triple negative breast cancer

更新时间：2025-12-31

- Progress on chemotherapy for triple negative breast cancer
- China Oncology Vol. 24, Issue 4, Pages: 316-320(2014)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.04.013
  CLC：
- Published Online：06 May 2014，
  
  Published：06 May 2014
- 稿件说明：
移动端阅览
倪晨,李婷,吴振华,胡夕春. 三阴性乳腺癌化疗进展[J]. 中国癌症杂志, 2014, 24(4): 316-320.

倪晨, 李婷, 吴振华, et al. Progress on chemotherapy for triple negative breast cancer[J]. China Oncology, 2014, 24(4): 316-320.
倪晨,李婷,吴振华,胡夕春. 三阴性乳腺癌化疗进展[J]. 中国癌症杂志, 2014, 24(4): 316-320. DOI： 10.3969/j.issn.1007-3969.2014.04.013.

倪晨, 李婷, 吴振华, et al. Progress on chemotherapy for triple negative breast cancer[J]. China Oncology, 2014, 24(4): 316-320. DOI： 10.3969/j.issn.1007-3969.2014.04.013.

摘要

三阴性乳腺癌作为乳腺癌的一种特殊亚型，对内分泌治疗和现有靶向治疗无效，并且通常复发较早、进展迅速、预后较差。现就三阴性乳腺癌的分子分型及其临床价值、化疗药物和化疗方案以及化疗和潜在的新靶点药物联合方面的最新进展作一综述。

Abstract

Triple negative breast cancer (TNBC)

as a special molecular subtype of breast cancer

is nonresponsive to endocrine therapy or commercially available targeted therapy. It is characterized by early recurrence

rapid progression and poor prognosis. This systemic and comprehensive overview was focused on recent progress on molecular subtyping of triple negative breast cancer and its possible clinical value

chemotherapeutic agents and chemotherapy regimens

and combination of chemotherapy with potential molecular targeting agents.

关键词

Keywords

references

Views

6164

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy

Prognostic significance of adjuvant chemotherapy in patients with gastric neuroendocrine carcinoma

New research advances and future prospect in precision treatment of triple-negative breast cancer

Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer

Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer

Related Author

Yang LIU

Yiyang HU

Yueping LIU

Shuyao NIU

Pingan DING

Yuan TIAN

Honghai GUO

Peigang YANG

Related Institution

Pathology Department, Fourth Hospital of Hebei Medical University

Department of the Third General Surgery, Fourth Hospital of Hebei Medical University

Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center

Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University

Center for Neuroendocrine Tumors, Department of Head, Neck and Neuroendocrine Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰